Xinnate secures 100 million SEK in financing and applies for a patent for the treatment of Epidermolysis Bullosa

Lund, Sweden, February 7, 2024


Helene Hartman, CEO, Xinnate

Xinnate conducted a new share issue of 100 million SEK from private investors last year. The funding enables an upcoming phase-2 study for the company's first drug—a gel for topical treatment of dysfunctional healing in wounds or inflammatory skin conditions. A phase-1 study in three parts is currently underway, including one part with patients suffering from the rare and severe disease Epidermolysis Bullosa. Planning for a multi-site phase-2 study with EB patients is ongoing.

– It is incredibly powerful that we can support the patent application with existing results from our clinical study. We aim to develop a drug that reduces harmful inflammation, improves the healing process, and reduces the risk of serious complications, says Helene Hartman, CEO of Xinnate.


Read full press release here